apremilast

Ligand id: 7372

Name: apremilast

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: apremilast

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 7
Hydrogen bond donors 1
Rotatable bonds 9
Topological polar surface area 127.46
Molecular weight 460.13
XLogP 2.06
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

References
1. Gudjonsson JE, Johnston A, Ellis CN. (2012)
Novel systemic drugs under investigation for the treatment of psoriasis.
J. Am. Acad. Dermatol., 67 (1): 139-47. [PMID:22305044]
2. Man HW, Schafer P, Wong LM, Patterson RT, Corral LG, Raymon H, Blease K, Leisten J, Shirley MA, Tang Y et al.. (2009)
Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor.
J. Med. Chem., 52 (6): 1522-4. [PMID:19256507]
3. Schafer P. (2012)
Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.
Biochem. Pharmacol., 83 (12): 1583-90. [PMID:22257911]
4. Schafer PH, Day RM. (2013)
Novel systemic drugs for psoriasis: mechanism of action for apremilast, a specific inhibitor of PDE4.
J. Am. Acad. Dermatol., 68 (6): 1041-2. [PMID:23680197]
5. Schafer PH, Parton A, Capone L, Cedzik D, Brady H, Evans JF, Man HW, Muller GW, Stirling DI, Chopra R. (2014)
Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.
Cell. Signal., 26 (9): 2016-29. [PMID:24882690]